Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$51 Mln
P/E Ratio
1.66
P/B Ratio
5.04
Industry P/E
--
Debt to Equity
-20.58
ROE
-54.75 %
ROCE
-259.69 %
Div. Yield
0 %
Book Value
--
EPS
0.38
CFO
$-323.87 Mln
EBITDA
$-576.16 Mln
Net Profit
$-565.93 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
CytomX Therapeutics (CTMX)
| -36.31 | 0.99 | -22.56 | -64.73 | -34.27 | -40.98 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
CytomX Therapeutics (CTMX)
| -33.33 | -3.13 | -63.05 | -33.89 | -21.18 | -44.97 | -28.34 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform... technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California. Address: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 Read more
Chairman & CEO
Dr. Sean A. McCarthy DPHIL
Chairman & CEO
Dr. Sean A. McCarthy DPHIL
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of CytomX Therapeutics Inc (CTMX) stood at $ 121 Mln as on 31-Dec-24
The share price of CytomX Therapeutics Inc (CTMX) is $0.66 (NASDAQ) as of 17-Apr-2025 16:28 EDT. CytomX Therapeutics Inc (CTMX) has given a return of -34.27% in the last 3 years.
CytomX Therapeutics Inc (CTMX) has a market capitalisation of $ 51 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of CytomX Therapeutics Inc (CTMX) is 1.66 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the CytomX Therapeutics Inc (CTMX) and enter the required number of quantities and click on buy to purchase the shares of CytomX Therapeutics Inc (CTMX).
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California. Address: 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Sean A. McCarthy DPHIL. is CytomX Therapeutics Inc (CTMX), and CFO & Sr. VP is Dr. Sean A. McCarthy DPHIL.
There is no promoter pledging in CytomX Therapeutics Inc (CTMX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| CytomX Therapeutics Inc. (CTMX) | Ratios |
|---|---|
|
Return on equity(%)
|
-133.06
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
23.08
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of CytomX Therapeutics Inc (CTMX) was $0 Mln.
$0.03
(
